McDermott advised eureKARE’s Biomedical Start-up Studio on the the Creation of EonBio, a New Biotech Company Co-Founded with Yeda that will Revolutionize Drug Discovery with Pioneering Cell-free Technology on a Chip

McDermott Will & Emery has advised eureKARE, investment company focused on financing and developing synthetic biology innovation across Europe, for the creation of EonBio, co-founded with Yeda, the commercial arm of the Weizmann Institute of Science in Israël, which has granted an exclusive license to EonBio under its “cell free technology” platform.

EonBio will further develop the “cell free technology platform”, a cutting-edge platform, to address high unmet medical need by reconstructing intricate bioproduction systems akin to the ones found in living cell.

The McDermott team that advised eureKARE was composed of Emmanuelle Trombe, partner, Anne-France Moreau, partner and Caroline Noyrez, lawyer (Transaction / Life Sciences)